These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 6405546)

  • 21. Possible glucagon-mediated hypocholesterolemic activity of a nicotinic acid derivative (sorbinicate).
    Uccella R; Morenghi R; Agosti C; Saponati G
    Artery; 1983; 11(5):400-12. PubMed ID: 6661043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Changes in the fatty acid composition of erythrocyte and platelet membranes after diet therapy in patients with hyperlipoproteinemia type II].
    Korf II; Meshcheriakova VA; Samsonov MA; Chepurnenko NV; Koshechkin VA
    Vopr Med Khim; 1987; 33(3):73-7. PubMed ID: 3630021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plafibride treatment and serum lipids in hyperlipoproteinemias.
    Rodriguez F; López IM; Jover E
    J Med; 1987; 18(3-4):153-63. PubMed ID: 3323393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of hypolipidemic treatment in inhibition of experimental atherosclerosis: the effect of nicotinic acid and related compounds.
    Parwaresch MR; Haacke H; Mäder C
    Atherosclerosis; 1978 Dec; 31(4):395-401. PubMed ID: 215172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
    Kaffarnik H; Schneider J; Schubotz R; Zöfel P; Hausmann L; Goebel KM
    Artery; 1980; 8(6):537-46. PubMed ID: 6114725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatty acid composition of serum lecithin and cholesterol ester in the normal menstrual cycle.
    Mattsson LA; Silfverstolpe G; Samsioe G
    Horm Metab Res; 1985 Aug; 17(8):414-7. PubMed ID: 4054830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
    Sznajderman M
    Pol Arch Med Wewn; 1980 Jun; 63(6):543-9. PubMed ID: 7402954
    [No Abstract]   [Full Text] [Related]  

  • 28. Fatty acid composition of serum lipids in bilharzial hepatic fibrosis and chronic active hepatitis.
    Gabr Y; Mahfouz M; Mohammed YS
    Acta Biol Med Ger; 1975; 34(1):45-51. PubMed ID: 1179920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Fatty acid metabolism in primary hyperlipoproteinemia].
    Reuter W
    Z Gesamte Inn Med; 1979 Oct; 34(20):suppl 287-9. PubMed ID: 398634
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of gemfibrozil on fatty acids in lipid fractions of plasma from patients with hypertriglyceridemia.
    Tavella M; Corder CN; McConathy W
    J Clin Pharmacol; 1993 Jan; 33(1):35-9. PubMed ID: 8429111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
    Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H
    MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined drug therapy for familial hypercholesterolemia.
    Packard CJ; Stewart JM; Morgan HG; Lorimer AR; Shepherd J
    Artery; 1980; 7(4):281-9. PubMed ID: 7213018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levels of linoleic acid and saturated and monounsaturated fatty acids in selected lipid fractions of the serum and platelets in patients with coronary arterial disease.
    Grójec M; Kaleta Z; Liszewska-Pfeifer D; Kobylińska U
    Acta Physiol Pol; 1983; 34(1):5-10. PubMed ID: 6637530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma and follicular fluid fatty acid profiles in dairy cows.
    Renaville B; Bacciu N; Comin A; Motta M; Poli I; Vanini G; Prandi A
    Reprod Domest Anim; 2010 Feb; 45(1):118-21. PubMed ID: 19055554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum lipoprotein fatty acid patterns in various types of familiar combined hyperlipidemia.
    Hrebícek J; Chmela Z; Skottová N; Bartek J; Vecera R
    Acta Univ Palacki Olomuc Fac Med; 1995; 139():19-23. PubMed ID: 8686553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum alpha tocopherol concentrations and cholesterol ester fatty acid composition in 70-year-old men reflect those 20 years earlier.
    Ohrvall M; Tengblad S; Gref CG; Salminen I; Aro A; Vessby B
    Eur J Clin Nutr; 1996 Jun; 50(6):381-5. PubMed ID: 8793419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemfibrozil--a new lipid lowering agent.
    Nash DT
    J Med; 1980; 11(2-3):107-16. PubMed ID: 6931871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.